Surveillance of vancomycin-resistant enterococci reveals shift in dominating clusters from vanA to vanB Enterococcus faecium clusters, Denmark, 2015 to 2022

Anette M. Hammerum*, Kasper Thystrup Karstensen, Louise Roer, Hülya Kaya, Mikkel Lindegaard, Lone Jannok Porsbo, Anne Kjerulf, Mette Pinholt, Barbara Juliane Holzknecht, Peder Worning, Karen Leth Nielsen, Sanne Grønvall Kjær Hansen, Marianne Clausen, Turid S. Søndergaard, Esad Dzajic, Claus Østergaard, Mikala Wang, Kristoffer Koch, Henrik Hasman

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

4 Citationer (Scopus)
3 Downloads (Pure)

Abstract

What did you want to address in this study and why?

Vancomycin is an antibiotic used to treat serious infections caused by multidrug-resistant bacteria. Vancomycin-resistant enterococci (VRE) are bacteria that can cause infections there are difficult to treat; they have become more frequent in Denmark and Europe in the last decade. Infections with VRE enterococci can be treated with another antibiotic: linezolid. We wanted to investigate how many vancomycin-resistant Enterococci were also resistant to linezolid.

What have we learnt from this study?

Detections of VRE in Denmark have increased from 520 isolates in 2015 to 827 isolates in 2022. During those years, the highest number of VRE occurred in the Capital Region of Denmark. From 2019 to 2022, VRE and VVE in this region decreased, but VRE increased in the Zealand Region, Central Denmark Region and North Denmark Region. Only 1% of the vancomycin-resistant enterococci were also resistant to linezolid.

What are the implications of your findings for public health?

The increase in VRE is of concern because this can lead to an increase in the use of other antimicrobial agents i.e. linezolid or daptomycin. Moreover, finding VRE that are also resistant to linezolid, even though the numbers are low, is a concern because the treatment options for such infections are very limited.

Citationsformater